Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2021

01-12-2021 | Overweight | Research

Interactions between Caveolin-1 (rs3807992) polymorphism and major dietary patterns on cardio-metabolic risk factors among obese and overweight women

Authors: Faezeh Abaj, Fariba Koohdani, Masoumeh Rafiee, Ehsan Alvandi, Mir Saeed Yekaninejad, Khadijeh Mirzaei

Published in: BMC Endocrine Disorders | Issue 1/2021

Login to get access

Abstract

Background

Caveolin-1 (CAV-1) is a cholesterol-dependent essential component located in caveolae. Several studies have been CAV-1 related to cardio-metabolic parameters in animal models, however, there are few studies in humans. Importantly, there is no study has investigated the interaction between CAV-1 rs3807992 gene and dietary patterns (DPs) on cardio-metabolic risk factors.

Methods

The current cross-sectional study was conducted on 404 overweight and obese women. Dietary intake was obtained from FFQ with 147 items. The CAV-1 genotype was measured by the PCR-RFLP method. The anthropometric measurements, serum lipid profile, and inflammatory markers were measured by standard protocols.

Results

There was a significant interaction between CAV-1 rs3807992 and healthy DP on high-density cholesterol (HDL) (P-interaction = 0.03), TC/HDL (P-interaction = 0.03) and high sensitivity C-reactive protein (hs-CRP) (P-interaction = 0.04); in A-allele carriers, higher following a healthy DP was related to a higher level of HDL and lower TC/HDL and hs-CRP. As well as, the significant interactions were observed between CAV-1 rs3807992 and unhealthy DP in relation to triglyceride (TG) (P-interaction = 0.001), aspartate aminotransferase (AST) (P-interaction = 0.01) and monocyte chemoattractant protein-1(MCP-1) (P-interaction = 0.01); A-allele carriers were more following the unhealthy DP had lower levels of TG, AST and MCP-1.

Conclusions

Our study revealed a significant gene-diet interaction between rs3807992 SNPs and DPs in relation to cardio-metabolic risk factors; A-allele carriers might be more sensitive to dietary composition compared to GG homozygotes. Following a healthy DP in A-allele-carriers may be improved their genetic association with cardio-metabolic risk factors.
Literature
8.
go back to reference Jew S, Antoine J-M, Bourlioux P, Milner J, Tapsell LC, Yang Y, et al. Nutrient essentiality revisited. J Funct Foods. 2015;14:203–9.CrossRef Jew S, Antoine J-M, Bourlioux P, Milner J, Tapsell LC, Yang Y, et al. Nutrient essentiality revisited. J Funct Foods. 2015;14:203–9.CrossRef
21.
go back to reference Cohen AW: Role of caveolin and caveolae in insulin signaling and diabetes. 2003, Role of caveolin and caveolae in insulin signaling and diabetes. Cohen AW: Role of caveolin and caveolae in insulin signaling and diabetes. 2003, Role of caveolin and caveolae in insulin signaling and diabetes.
22.
27.
go back to reference Mirmiran P, Hosseini-Esfahani F, Mehrabi Y, Hedayati M, Azizi F. Reliability and relative validity of an FFQ for nutrients in the Tehran lipid and glucose study. Public Health Nutr. 2009;13:654–62.CrossRefPubMed Mirmiran P, Hosseini-Esfahani F, Mehrabi Y, Hedayati M, Azizi F. Reliability and relative validity of an FFQ for nutrients in the Tehran lipid and glucose study. Public Health Nutr. 2009;13:654–62.CrossRefPubMed
34.
go back to reference Haddad D, Al Madhoun A, Nizam R, Al-Mulla F. Role of Caveolin-1 in diabetes and its complications. Oxidative Med Cell Longev. 2020;2020:9761539.CrossRef Haddad D, Al Madhoun A, Nizam R, Al-Mulla F. Role of Caveolin-1 in diabetes and its complications. Oxidative Med Cell Longev. 2020;2020:9761539.CrossRef
37.
go back to reference Tofovic SP, Branch KR, Oliver RD, Magee WD, Jackson EK. Caffeine potentiates vasodilator-induced renin release. J Pharmacol Exp Ther. 1991;256(3):850–60.PubMed Tofovic SP, Branch KR, Oliver RD, Magee WD, Jackson EK. Caffeine potentiates vasodilator-induced renin release. J Pharmacol Exp Ther. 1991;256(3):850–60.PubMed
Metadata
Title
Interactions between Caveolin-1 (rs3807992) polymorphism and major dietary patterns on cardio-metabolic risk factors among obese and overweight women
Authors
Faezeh Abaj
Fariba Koohdani
Masoumeh Rafiee
Ehsan Alvandi
Mir Saeed Yekaninejad
Khadijeh Mirzaei
Publication date
01-12-2021
Publisher
BioMed Central
Keyword
Overweight
Published in
BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-021-00800-y

Other articles of this Issue 1/2021

BMC Endocrine Disorders 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.